S.s. Mortazavi Farsani, M. Sadeghizadeh, H. Shirzad, F. Najafi,
Volume 10, Issue 4 (Fall 2019)
Abstract
Aims: Hematopoietic stem cells are responsible for the production of blood cells in the bone marrow. During the process of differentiation, these cells commitment to two precursor cell lines include myeloid and lymphoid cells. Various blood cells, excluded lymphocytes, generates from myeloid cells. Some patients with severe anemia or thrombocytopenia receive hematopoietic stem cell through transplantation. Finding a potential component for inducing differentiation of hematopoietic stem cells before transplantation, could be an appropriate strategy for the acceleration of blood cells production in recipient persons. Various studies indicate the ability of Curcumin for inducing of cell differentiation. This component can alter many of cellular mechanisms.
Material and methods: The aim of this project was to evaluate the effects of Nanocurcumin on mRNA expression levels of GATA1, GATA2, c-Myb and Hhex genes and alteration of cellular ROS in umbilical cord blood-derived hematopoietic stem cells. Nanocurcumin was synthesized from Curcumin, Oleic acid, and PEG400. The rate of Nanocurcumin delivery into the cells was also evaluated.
Findings: Our results show that intracellular ROS and expression levels of GATA1, c-Myb, and Hhex transcription factors were significantly increased after treatment with Nanocurcumin (p<0.05). These transcription factors involve in myeloid differentiation.
Conclusion: Enhancement of these transcription factors expression making Nanocurcumin a potential candidate for applying in myeloid differentiation media and basic and clinical studies.
Rezvaneh Vahedian Sadeghi, Masoud Parsania, Majid Sadeghizadeh, Setareh Haghighat, Seyedeh Sahar Mortazavi Farsani,
Volume 13, Issue 1 (3-2022)
Abstract
Abstract
Introduction: Cervical cancer is the fourth most common cancer among women. In recent years, attention has increased to natural products such as curcumin with anti-cancer potential as a therapeutic supplement. However, due to its poor solubility, its clinical use is limited. In this regard, in this study, to improve clinical parameters, the effects of nanocurcumin on the angiogenesis inhibition of cervical cancer were investigated and compared with free curcumin.
Materials and Methods: MTT method was used to evaluate the proliferation of the HeLa cell line with free curcumin and nanocurcumin at different doses and time intervals and the rate of apoptosis was assessed by flow cytometry. Then, the expression of the vascular endothelial growth factor (VEGF-A) gene in HeLa cells was measured by Real-Time PCR and Western blotting, respectively.
Results: According to IC50 for 48 hours in the HeLa cell line, which was 15 μM/ml and 50 μM/ml for nanocurcumin and free curcumin, respectively, the nanocurcumin showed a greater lethal effect. VEGF-A gene expression (p <0.0001) and protein level (p <0.01) were significantly lower following nano-curcumin treatment than free curcumin.
Conclusion: Nanocarrier increased the solubility and further inhibited the proliferation of cervical cancer HeLa cells and was three times more effective than curcumin in inhibiting angiogenesis at the same concentration. Therefore, nanocurcumin can be a good option for drug supplementation along with routine cervical cancer treatment.
Keywords: Cervical cancer, Nanocurcumin, HeLa cell, VEGF-A.
